Nuvalent shares surged on Tuesday after GSK announced it would acquire the Nasdaq-listed biotech firm for $10.6 billion, or $124 per share in cash. The stock rose 38.9% to $122.93, nearly reaching the offer price and reflecting a typical merger-arbitrage trade.
The jump was not part of a broader biotech rally. The SPDR S&P Biotech ETF rose 2.1%, while the iShares Nasdaq Biotechnology ETF gained 1.4%, indicating Nuvalent's move was company-specific rather than sector-wide.
The deal centers on Nuvalent's two lead lung-cancer drugs, zidesamtinib and neladalkib, both currently under review by the U.S. Food and Drug Administration. The FDA has set target decision dates for September 18 and November 27. Both drugs target non-small cell lung cancer, the most common form, with ROS1 and ALK gene mutations providing clear therapeutic targets.
GSK plans to launch a tender offer within the next 10 business days, asking Nuvalent shareholders to sell their shares directly to the company. The offer represents a 40% premium to Nuvalent's last closing price and a 26% premium above its 30-day volume-weighted average price.
GSK CEO Luke Miels described the acquisition as a "multi-product deal" and stated that the two main drugs could become "significant new treatment options" if approved. Nuvalent CEO James Porter said GSK's global reach would help bring zidesamtinib and neladalkib to market and support what he called "practice-changing innovation."
Miels told reporters the deal is outside GSK's normal range, calling it "unusual" and "essentially three products in one." James Eugene, an analyst at Verso Investment Management, noted that some investors may have been surprised by the size, as many expected GSK to pursue deals worth $2 billion to $4 billion.
GSK is seeking to strengthen its oncology portfolio, which currently accounts for only 6% of its total sales, compared to AstraZeneca's 44% from cancer drugs. GSK's U.S. shares were flat in early trading.
Following the announcement, analysts quickly adjusted their ratings. H.C. Wainwright downgraded Nuvalent to neutral from buy and cut its target price to $124 from $155. Wells Fargo shifted to equal weight from overweight and raised its target to $124 from $116.
An SEC filing indicates the deal is not subject to a financing condition. However, it requires more than half of Nuvalent's Class A shares to be tendered and must receive approval under the Hart-Scott-Rodino Antitrust Improvements Act. Affiliates of Deerfield Management and certain Nuvalent directors and officers, who collectively hold about 28% of Class A shares, have already agreed to tender their shares.
If neladalkib gains regulatory approval and enters the market, it will face competition from Pfizer's Lorbrena and Roche's Alecensa, both ALK-targeting drugs. The trade carries risks: if the FDA delays approval or grants a narrower label than expected, the value of Nuvalent's drugs could decline. The deal could also be delayed by tender, antitrust, or other closing conditions. In the event of a break-up, Nuvalent would owe GSK a termination fee of $350.475 million.
Currently, Nuvalent shares are trading near the cash offer price, leaving minimal room for upside unless a competing bidder emerges. The narrow spread primarily reflects timing, regulatory approvals, and the likelihood of deal completion.
